CAMP4 Therapeutics Corporation Revenue
CAMP4 Therapeutics Corporation (CAMP) reported Revenue of $1.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-08-13
- CAMP4 Therapeutics Corporation revenues for the quarter ending 2026-06-30 was $1.78M, a 18.84% increase year-over-year.
- CAMP4 Therapeutics Corporation revenues for the quarter ending 2026-03-31 was $1.29M, a 50.82% increase year-over-year.
- CAMP4 Therapeutics Corporation revenues for the quarter ending 2025-06-30 was $1.50M.
- CAMP4 Therapeutics Corporation revenues for the quarter ending 2025-03-31 was $858.00K.
- CAMP4 Therapeutics Corporation revenues for fiscal 2025 was $3.50M, a 436.50% increase from fiscal 2024.
- CAMP4 Therapeutics Corporation revenues for fiscal 2024 was $652.00K, a 86.29% increase from fiscal 2023.
- CAMP4 Therapeutics Corporation revenues for fiscal 2023 was $350.00K.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.78M 10-Q · filed 2026-08-13 | $3.07M 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $1.29M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $3.50M 10-K · filed 2026-03-05 | |||
| 2025-06-30 | $1.50M 10-Q · filed 2026-08-13 | $2.35M 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $858.00K 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $652.00K 10-K · filed 2026-03-05 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $350.00K derived: sum of 2 quarters · filed 2025-03-27 | $350.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $350.00K 10-Q · filed 2024-11-21 | $350.00K 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |